ViewRay, Inc. (Nasdaq: VRAY) announced today an order for the company’s MRIdian® MR image-guided linac at the University Hospital Zurich (USZ) in Zurich, Switzerland. The order formalizes the previously announced tender award from the Swiss National R’Equip programme. Once commissioned, the USZ MRIdian system will be the first in Switzerland, and among the first MR-guided linac systems in Europe to treat patients.

USZ is one of the largest and most important teaching hospitals in Europe, renowned for its health care and research achievements. The USZ tender award process included a competitive and comprehensive technology review. According to the tender award, MRIdian was selected as the “only device that met all the latest technological requirements” and “could fit into the existing premises as a replacement device,” highlighting the system’s unique capabilities and ability to fit into standard radiotherapy vaults.

Professor Matthias Guckenberger, M.D., chairman of the Department of Radiation Oncology at USZ said, “MRIdian brings a level of real-time visibility and treatment adaptation that is not possible using standard radiation therapy technology.” He added, “We look forward to expanding our offerings to include MRIdian’s advanced imaging and delivery capabilities to enhance the level of care we bring to our patients.”

Unlike conventional radiotherapy, the MRIdian system provides diagnostic-quality MR visualization of soft-tissue targets and surrounding organs. This technological advance enables daily on-table treatment plan adaptation to quickly and dynamically adjust for subtle anatomical changes that may occur, both during treatment delivery and throughout the course of treatment. Combined, these capabilities provide the potential for clinicians to improve targeting precision and thus deliver higher, and potentially more effective, radiation doses.

A key focus of USZ’s MRIdian MR image-guided radiation therapy program will be MR-guided adaptive radiotherapy, particularly stereotactic radiosurgery for treating oligo-metastatic disease, head and neck, and lung cancer. The MRIdian Linac will also be utilized as part of the hospital’s Radiomics biomarker research for response prediction and assessment, in collaboration with the Swiss Federal Institute of Technology in Zurich (ETH), which is ranked among the top universities in the world.